RATIONALE: PD 0332991 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well PD 0332991 works in treating patients with refractory solid tumors.
Completed
Phase 2
| Drug | Synonyms | Arms |
|---|---|---|
| PD-0332991 | Palbociclib | Arm 1 - Metastatic breast cancer |
PRIMARY OBJECTIVES:
I. To determine the response rates following treatment with PD 0332991 in the following
malignancies: 1) Metastatic breast cancer, 2) Metastatic colorectal cancer, 3) Metastatic
melanoma with CDK4 mutation or amplification, or 4) Cisplatin-refractory, unresectable germ
cell tumors.
OUTLINE:
Patients receive oral PD 0332991 once daily on days 1-21. Treatment repeats every 28 days for
up to 12 courses in the absence of unacceptable toxicity or disease progression.
| Name | Type | Description | Interventions |
|---|---|---|---|
| Arm 1 - Metastatic breast cancer | Experimental | Metastatic breast cancer PD-0332991 Given orally, 125 mg QD on a 21-day |
|
| Arm 2 - Metastatic colorectal cancer that harbors the Kras or BRAF mutation | Experimental | Metastatic colorectal cancer that harbors the Kras or BRAF mutation PD-0332991 Given orally, 125 mg QD on a 21-day |
|
| Arm 3 - Advanced or metastatic esophageal and/or gastric cancer | Experimental | Advanced or metastatic esophageal and/or gastric cancer PD-0332991 Given orally, 125 mg QD on a 21-day |
|
| Arm 4 - Cisplatin-refractory, unresectable germ cell tumors | Experimental | Cisplatin-refractory, unresectable germ cell tumors PD-0332991 Given orally, 125 mg QD on a 21-day |
|
| Arm 5 - CCND1amplification, CDK4/6mutation, CCND2amplification, OR other functional G1/S alterations | Experimental | Any tumor type if tissue tests positive for CCND1 amplification, CDK4/6 mutation , CCND2 amplification OR any other functional alteration at the G1/S checkpoint. PD-0332991 Given orally, 125 mg QD on a 21-day |
|
Inclusion Criteria:
- Disease Characteristics:
All Subjects: All subjects treated under this protocol will have histologically documented
cancer of one of the following types:
A. Metastatic breast cancer (7 triple negative, 23 ER+ after the first 15 patients are
enrolled on the non-CCND1cohort; in addition 10 HER2+ for combination trastuzumab and
PD0332991 therapy) up to 55 total enrollment slots B. Metastatic colorectal cancer that
harbors the Kras or BRAF mutation (15-30 enrollment slots) C. Advanced or metastatic
esophageal and/or gastric cancer (15-30 enrollment slots) D. Cisplatin-refractory,
unresectable germ cell tumors (15-30 enrollment slots) E. Any tumor type if tissue tests
positive for CCND1 amplification, CDK4/6 mutation, CCND2 amplification OR any other
functional alteration at the G1/S checkpoint. (15-30 enrollment slots)
- Biopsy Requirements: For Subjects with accessible disease amenable to biopsy: A biopsy
will be obtained pre-treatment and in during cycle 1 (while patient is receiving drug) for
molecular markers of the cell cycle, and its inhibition.
- Subjects will be > 18 years old
- The subject has disease that is assessable by tumor marker, physical, or radiologic
means.
- The subject has an Eastern Cooperative Oncology Group (ECOG) performance status of 0
or 1.
- The subject has adequate organ function, defined as follows A. Bilirubin ≤ 1.5 x the
upper limit of normal (ULN) B. Serum creatinine ≤ 1.5 x UNL or calculated creatinine
clearance ≥ 60 mL/min, and C. For subjects without liver metastases: alanine
aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN D. For
subjects with liver metastases: alanine aminotransferase (ALT) and aspartate
aminotransferase ≤ 5 x ULN
- All tumors must test positive for Rb expression except:
A. ER positive metastatic breast tumors (data now shows all to be Rb positive.) B. Any
tumor type if tissue tests positive for CCND1 amplification, CDK4/6 mutation, CCND2
amplification OR any other functional alteration at the G1/S checkpoint.
- The subject has adequate marrow function, defined as follows: A. Absolute neutrophil
count (ANC) >1500/mm3 B. Platelets >100,000/mm3, and C. Hemoglobin > 9 g/dL
- The subject is capable of understanding and complying with the protocol requirements
and has signed the informed consent document.
- Sexually active subjects (male and female) must use accepted methods of contraception
during the course of the study and for 3 months after the last dose of protocol
drug(s).
- Female subjects of childbearing potential must have a negative pregnancy test at
screening. Females of childbearing potential are defined as sexually mature women
without prior hysterectomy or who have had any evidence of menses in the past 12
months.
- However, women who have been amenorrheic for 12 or more months are still considered to
be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy,
antiestrogens, or ovarian suppression.
Exclusion Criteria
- The subject has received cytotoxic chemotherapy (including investigational cytotoxic
chemotherapy) within 3 weeks (or nitrosoureas or mitomycin C within 6 weeks) before
the first dose of PD 0332991. . Patients with HER2-overexpressing tumors may receive
trastuzumab up to the date of starting therapy, and may continue to receive
trastuzumab while receiving PD0332991.
- The subject has received any other type of investigational agent within 28 days before
the first dose of study treatment.
- The subject has not recovered from clinically-meaningful toxicity due to prior therapy
(i.e., back to baseline or Grade ≤ 1), with the exception of neurotoxicity and
alopecia.
- The subject has untreated or uncontrolled brain metastases or evidence of
leptomeningeal involvement of disease unless the subject has a teratoma in which case
s/he may be eligible if all other eligibility criteria are met
- The subject has uncontrolled intercurrent illness including, but not limited to:
1. ongoing or active infection
2. diabetes mellitus
3. hypertension
4. symptomatic congestive heart failure, unstable angina pectoris, stroke or
myocardial infarction within 3 months
- The subject has a baseline corrected QT interval (QTc) > 470 ms.
- The subject is pregnant or breastfeeding.
- The subject is known to be positive for the human immunodeficiency virus (HIV). Note:
baseline HIV screening is not required
- The subject is unable or unwilling to abide by the study protocol or cooperate fully with
the investigator or designee.
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | 18 Years |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
| Measure: | Response Rates |
| Time Frame: | 10 years |
| Safety Issue: | |
| Description: | Response rates will be measured using the Response Evaluation Criteria in Solid Tumors (RECIST): Complete Response (CR) - Disappearance of all target lesions Partial Response (PR) - ≥30% decrease in the sum of the longest diameter of the target lesions compared with baseline Progressive Disease (PD) - ≥20% increase in the sum of the longest diameter of the target lesions compared with the smallest sum of the longest diameter recorded since treatment started OR The appearance of 1 or more new lesions Stable Disease (SD) - Neither PR or PD Not Evaluable (NE) |
| Phase: | Phase 2 |
| Primary Purpose: | Interventional |
| Overall Status: | Completed |
| Lead Sponsor: | Abramson Cancer Center of the University of Pennsylvania |
March 11, 2021
